Core Viewpoint - The pharmaceutical sector is experiencing a mixed performance in 2025, with a significant number of companies forecasting profit increases, while others are facing substantial losses. Group 1: Profit Forecasts - A total of 283 pharmaceutical stocks have disclosed their 2025 earnings forecasts, with 160 companies expecting year-on-year profit growth. Among these, Sino Medical has the highest projected increase, with an expected profit growth of over 32 times [1][4]. - WuXi AppTec is anticipated to achieve a record net profit of 19.15 billion yuan, marking the highest since its listing. This includes nearly 5.6 billion yuan in non-recurring gains from the sale of equity interests [6]. - Sino Medical's projected net profit for 2025 is between 43 million and 50 million yuan, reflecting a year-on-year increase of 2,767% to 3,233%. The growth is attributed to stable revenue from its neuro-interventional business and a 22% increase in its coronary intervention business due to the implementation of a national procurement policy [4][5]. Group 2: Loss Forecasts - Over 120 companies are forecasting profit declines for 2025, with 39 facing their first losses since going public, including companies like Zhifei Biological and Zhenbao Island. Zhifei is expected to report a loss of between 10.698 billion and 13.726 billion yuan, a decline of 630% to 780% compared to the previous year [2][8]. - Zhenbao Island anticipates a net loss of between 1.012 billion and 1.173 billion yuan, attributed to delays in the procurement process and increased cost control measures [8]. - Huiyu Pharmaceutical's losses are primarily due to non-core investment losses, with a fair value loss of 173 million yuan from its investment in Zhejiang Tongyuan Kang Pharmaceutical [9]. Group 3: Innovative Drug Companies - The innovative drug sector is showing signs of recovery, with companies like Nocera and Rongchang Biopharma expected to turn losses into profits. Nocera forecasts a net profit of approximately 633 million yuan, a significant increase from the previous year [3][11]. - Rongchang Biopharma is also expected to achieve profitability with projected revenues of around 3.25 billion yuan, a year-on-year increase of about 89% [11]. - Companies like Junshi Biosciences are reducing their losses significantly, with an expected net loss of around 873 million yuan, a reduction of 408 million yuan compared to the previous year [11][12].

Summary of Key Points Core Viewpoint - The A-share market experienced significant block trading activity on February 3, with a total transaction value of 2.236 billion yuan, highlighting notable trading in specific stocks such as Shanghai Airport, Zijin Mining, and Longjing Environmental Protection [1]. Group 1: Block Trading Activity - A total of 80 stocks underwent block trading, with Shanghai Airport leading at 349 million yuan, followed by Zijin Mining at 274 million yuan and Longjing Environmental Protection at 161 million yuan [1]. - Among the stocks traded, 7 were sold at par value, 2 at a premium, and 71 at a discount, indicating a predominance of discounted trades [1]. Group 2: Premium and Discount Rates - The stocks with the highest premium rates were DeMa Technology at 5.67% and Shen High-Speed at 2.01% [1]. - The stocks with the highest discount rates included Kai Fa Technology at 29.94%, New Wave Shares at 23.56%, and Ai Meike at 23.43% [1]. Group 3: Institutional Buying and Selling - The top institutional buying positions included Shanghai Airport at 349 million yuan, Longxin Zhongke at 116 million yuan, and Xinyuan Shares at 60.575 million yuan [2]. - The leading institutional selling positions were Nanxin Technology at 8.4 million yuan and Guobo Electronics at 4.1784 million yuan [2].

截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 2. 股份分類 | 普通股 | A 股份類別 | | | 於香港聯交所上市 (註1) | | 否 ...

Market Overview - The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is projected to grow from USD 258.88 billion in 2025 to USD 275.27 billion in 2026, reaching USD 374.68 billion by 2031, with a CAGR of 6.33% from 2026 to 2031 [2]. Market Drivers - There is a robust outsourcing demand for complex biologics, high-potency APIs (HPAPIs), and AI-enabled process-development platforms, which are driving market growth [3]. - Increasing outsourcing volume by large pharmaceutical companies is influenced by escalating R&D costs and pipeline complexity, leading to a preference for asset-light models that leverage CDMO expertise [5]. - The surge in biologics and complex-molecule pipelines is evident, with biological entities dominating new-drug filings, including antibody-drug conjugates and mRNA vaccines [6]. Geographic Insights - North America held a 37.95% revenue share in 2025, supported by premier biologics programs and a deep venture-capital pool [9]. - The Asia-Pacific region is expected to grow at the fastest rate of 7.18% CAGR through 2031, with significant investments in mega-plants for mAbs and oligonucleotides [10]. - Europe is experiencing steady expansion, with Germany and the UK leading in quality and innovation despite Brexit challenges [11]. Market Trends - Consolidation in the industry is evident, as seen in Novo Holdings' USD 16.5 billion acquisition of Catalent, indicating a shift towards end-to-end CDMO providers [4]. - The demand for specialist partners is amplified by the need for compliance with stringent multi-region regulatory requirements, which challenge smaller entrants [8]. Competitive Landscape - Major players in the market include Thermo Fisher Scientific, Lonza Group, Catalent, and Samsung Biologics, among others, with strategic moves and market share analysis highlighting their competitive positioning [17].

| 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 2. 股份分類 ...

Core Insights - The global CXO industry is entering a new phase, with leading companies adopting a strategy to build a "diversified yet centralized" global network [1] - Due to geopolitical tensions and fluctuating tariff policies, global pharmaceutical outsourcing companies need to implement cross-regional diversification strategies to balance local and overseas production capacities [1] - WuXi AppTec's (药明康德) strategic deployment over the past few years aligns with this industry consensus, demonstrating its effectiveness through consistently exceeding performance expectations [1] Financial Performance - WuXi AppTec expects total revenue to reach 45.46 billion yuan in 2025, representing a year-on-year increase of 15.84%, with a 21.40% increase in revenue from continuing operations [1] - The adjusted Non-IFRS net profit attributable to the parent company is projected to be 14.96 billion yuan, reflecting a year-on-year growth of 41.3% [1] - The company is set to achieve record-high free cash flow in 2025, supported by capital expenditures of 5.5 to 6 billion yuan [3] Global Operations - WuXi AppTec has established a global operational system with over 20 R&D and production bases across Asia, Europe, and North America, serving approximately 6,000 clients [5] - The company is accelerating global capacity expansion to create a flexible and reliable global supply chain network, which will be crucial for capturing global market opportunities [5] Strategic Partnerships - In addition to consolidating traditional markets, WuXi AppTec has made strategic moves into emerging regions, signing memorandums of understanding with NEOM and the Saudi Ministry of Health [7] - These partnerships lay the groundwork for establishing a world-class CRDMO R&D and production base in NEOM and other areas in Saudi Arabia, marking a significant step in expanding its global network into the Middle East [7]

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Aimeike with a 2.18% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 41.83 million yuan, totaling 234 million yuan, averaging 19.54 million yuan per day [1] - Policy support for the pharmaceutical industry is ongoing, with Shanghai accelerating the implementation of major industrial projects in fields such as integrated circuits, biomedicine, and artificial intelligence [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the total index weight [2] - The success rate of Phase I clinical trials for dozens of AI-derived pipelines entering trials in 2025 is projected to be as high as 80%-90%, significantly exceeding traditional levels of 40%-65% [1]

Group 1 - The core viewpoint of the news is that WuXi AppTec experienced a decline in stock price and trading volume, with significant financing activities indicating a mixed sentiment among investors [1][2]. Group 2 - On February 2, WuXi AppTec's stock fell by 2.10%, with a trading volume of 3.425 billion yuan. The financing buy-in amount was 207 million yuan, while the financing repayment was 314 million yuan, resulting in a net financing outflow of 107 million yuan [1]. - As of February 2, the total balance of margin trading for WuXi AppTec was 6.364 billion yuan, with the financing balance of 6.349 billion yuan accounting for 2.75% of the circulating market value, which is above the 70th percentile level over the past year [1]. - In terms of securities lending, on February 2, WuXi AppTec repaid 18,600 shares and sold 4,400 shares, with a selling amount of 410,100 yuan. The remaining securities lending volume was 151,700 shares, with a balance of 14.1344 million yuan, which is below the 20th percentile level over the past year [1]. Group 3 - WuXi AppTec, established on December 1, 2000, and listed on May 8, 2018, provides a comprehensive platform for the discovery, development, and production of small molecule chemical drugs, serving global pharmaceutical companies [2]. - The company's revenue composition includes 78.37% from chemical business, 12.93% from testing services, 6.02% from biological services, and 1.90% from other supplementary services [2]. - For the period from January to September 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61%, and a net profit attributable to shareholders of 12.076 billion yuan, with a year-on-year increase of 84.84% [2]. Group 4 - Since its A-share listing, WuXi AppTec has distributed a total of 14.06 billion yuan in dividends, with 10.406 billion yuan distributed over the past three years [3]. - As of September 30, 2025, the top ten circulating shareholders of WuXi AppTec included Hong Kong Central Clearing Limited as the second-largest shareholder, holding 249 million shares, a decrease of 52.6071 million shares from the previous period [3]. - Other notable shareholders include Huaxia SSE 50 ETF and Huatai-PB CSI 300 ETF, which have also seen reductions in their holdings [3].

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Core Insights - The report emphasizes the continuous growth potential in the innovative pharmaceutical sector, particularly focusing on CXO, innovative drugs, and high-value consumables as key investment areas for 2025 [5][10][11] Performance Forecast - As of February 1, 2025, 261 pharmaceutical companies listed on A-shares have released performance forecasts, with 129 companies expected to be profitable. Among these, 85 companies anticipate profit growth, while 44 expect declines, and 25 are projected to turn losses into profits [6][7] - The report predicts the following profit growth rates for 28 pharmaceutical companies in 2025: - 2 companies with growth rates of 40% or more: SaiFen Technology and JiuZhou Pharmaceutical - 8 companies with growth rates between 20% and 40%: ZuoLi Pharmaceutical, AoRuiTe, HaoYuan Pharmaceutical, BiDe Pharmaceutical, DaSanLin, WoWu Biological, TeBao Biological, and HengRui Pharmaceutical - 10 companies with growth rates between 10% and 20%: BaiYunShan, LingRui Pharmaceutical, KaiLaiYing, PuRuiSi, YaoKang Biological, XiangSheng Medical, KeFu Medical, YiFeng Pharmacy, XinLiTai, and LanXiao Technology - 7 companies with growth rates between 0% and 10%: YunNan BaiYao, WeiEr Pharmaceutical, TongCe Medical, DongFuLong, JingXin Pharmaceutical, EnHua Pharmaceutical, and HuaDong Pharmaceutical - 1 company expected to turn losses into profits: BeiJi ShenZhou-U [7][8] Sector Analysis - The report highlights significant growth in the CXO, innovative drug, and high-value consumables sectors for 2025, driven by favorable conditions in the global innovative drug industry, increased order signing, and rising investment sentiment in both domestic and international pharmaceutical markets [10][11] - The high-value consumables sector benefits from the recovery of domestic surgical demand and improved profit margins following stabilized procurement prices. Some traditional Chinese medicine companies have also exceeded market expectations [10][11] - In contrast, sectors such as IVD, raw materials, vaccines, and blood products are facing performance pressures [10][11] Investment Recommendations - The report continues to recommend focusing on the innovative drug and CXO sectors, with specific companies highlighted for attention: - CXO sector: WuXi AppTec, Kanglong Chemical, KaiLaiYing, HaoYuan Pharmaceutical, BaiAoSaiTu, Tigermed, NuoSiGe, ZhaoYan Pharmaceutical, YiNuoSi, and PuRuiSi - Innovative drug sector: HengRui Pharmaceutical, BeiJi ShenZhou-U, NuoCheng JianHua, AiDi Pharmaceutical, and WeiXing Biological [5][10]